Venter teams with Cleveland Clinic on aging; Redx launches immunology offshoot;

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Circassia snags a pair of asthma biotechs for $376M. Report | Follow @JohnCFierce

@DamianFierce: Wait did they just invent NantPharma for this deal? Is there a geneology chart for the NantFamily? Release | Follow @DamianFierce

> J. Craig Venter's Human Longevity is joining forces with Cleveland Clinic for a human genomics collaboration aimed at disease discovery, a little more than a year after the company kicked off operations with the promise of building the world's biggest human gene-sequencing platform. Story

> Redx Pharma launched its third subsidiary, focused on immunology and promising to deliver up to 8 new drug candidates over the next few years. More

> AbbVie's ($ABBV) blockbuster Humira won FDA approval for use in the hidradenitis suppurativa, a chronic inflammatory skin disease. News

Medical Device News

@FierceMedDev: Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. Article| Follow @FierceMedDev

@VarunSaxena2: Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Article | Follow @VarunSaxena2

@EmilyWFierce: OncoCyte ropes in $7M for cancer diagnostic R&D. FierceDiagnostics story | Follow @EmilyWFierce

> Data presented at cardiology conference show Abbott's MitraClip can cut arrhythmias in half. More

> Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Report

Pharma News

@FiercePharma: Japan's MHLW sets Sovaldi price, hep C competition heats up. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing this week: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds. Report | Follow @CarlyHFierce

> Eisai predicts long-awaited operating profit rise for fiscal 2015. Article

> AbbVie nabs FDA's orphan drug tag for Humira in HS. Item

> New CEO Weber deals with Takeda's loss and promises brighter future. Report